In this study we investigated the additive effect of apraclonidine 0.5% used three times daily in conjunction with timolol maleate 0.5% solution used twice daily in exfoliation versus primary open-angle glaucoma patients.
Materials and methods
We entered into this prospective study consecutive newly diagnosed phakic Greek patients with either exfoliation or primary open-angle glaucoma in whom therapy with timolol maleate 0.5% twice daily alone was deemed inadequate for controlling their lOP and whose lOP on this medicine was> 21 mmHg at 08:00 hours at the first diurnal curve. In patients with bilateral glaucoma one eye was randomly selected to be included in the study. Patients were diagnosed and followed at the Glaucoma Unit of the University Department of Ophthalmology, AHEP A Hospital, Thessaloniki, Greece which meets the ophthalmic needs of an urban and rural population of approximately 1.5 million people. All new eligible glaucoma patients who presented between July 1996 and June 1997 and were treated with timolol maleate 0.5% b.Ld. were invited to participate in this study. Some patients had been included in a previous report that detailed the effect of timolol on the diurnal curve of IOP.u Three patients declined participation due to the inconvenience of hospitalisation. All patients provided their written informed consent before participation in this study. A specially designed adverse experience report was completed for each patient receiving apraclonidine 0.5%.
The inclusion and exclusion criteria for this study were similar to those described previously.2,lo Patients with conditions that might affect the accuracy and reliability of the lOP readings (e.g. concurrent ocular inflammation, previous ocular surgery, ophthalmic drugs, thyroid ophthalmopathy) were excluded. To facilitate age matching all primary open-angle glaucoma patients younger than 50 years and all exfoliation glaucoma patients older than 80 years were excluded from the study. Eligible patients by the above criteria were matched individually for age (± 2 years) between the exfoliation and primary open-angle glaucoma groupS.2,IO Upon admittance to the study a standard protocol was used in all patients.IO An initial ocular examination was performed including Snellen visual acuity, Goldmann applanation tonometry, examination of the ocular adnexa, slit-lamp biomicroscopy, gonioscopy and stereoscopic visualisation of the fundus with the Yolk 90 D lens. The Octopus 500 EZ perimeter (G1 program; analysis by Peridata 6.2c) was used for testing visual field defects. All glaucoma patients were comprehensively examined on presentation by slit-lamp biomicroscopy and gonioscopy to determine whether they had exfoliation or primary open-angle glaucoma. Patients included in the exfoliation glaucoma group had clinical evidence of exfoliation material in the anterior segment. By contrast, patients diagnosed as suffering from primary open-angle glaucoma had no evidence of exfoliation material. Information recorded on all patients included: sex, age, systemic disorders, systemic drugs and details of glaucoma at the time of diagnosis (lOP, cup-to-disc ratio, visual field). The mean defect, as determined by the Octopus perimeter, was used to assess the visual field.
Following the initial examination all patients were treated with timolol maleate 0.5% solution (Merck Sharp & Dohme/Vianex, Athens) twice daily with the dosing regimen set at 08:00 and 20:00 hours. Patients were admitted to hospital for the baseline 24 h diurnal curve of their lOP on timolol after at least 3 months of chronic dosing with timolol maleate. Pressure measurements were performed by the same investigators (D.A.M., T.M.) using the same instrument (Goldmann applanation tonometer). Patients were admitted in the morning and measurements were performed every 4 ha t 10:00, 14:00, 18:00, 22:00, 02:00, 06:00 and 08:00 hours. At the 22:00 hours measurement patients were awake at bed rest. The 06:00 hours lOP measurement was performed immediately after waking. Patients were encouraged to carry on as normal a life as possible within the hospital.
Following discharge from the hospital all patients whose lOP was not controlled sufficiently by timolol alone (Le. lOP> 21 rnmHg at 08:00 hours) were started on apraclonidine 0.5% drops (Alcon Hellas, Athens) t.Ld. (dosing regimen set at 08:00, 14:00 and 20:00 hours). Patients were advised how to instil their eyedrops and were instructed for compliance with their medication. Apraclonidine drops were instilled approximately 10 min after timolol drops. Patients who could not comply were excluded. All 60 patients who completed the dosing regimen were readmitted approximately 2 months after their first diurnal lOP curve with timolol for a second 24 h lOP curve while using their apraclonidine and timolol drops.
Statistical analysis of the lOP at each time point was by an unpaired t-test between groups. A paired t-test was used to evaluate the reduction in lOP from baseline within groups after the addition of apraclonidine. Controlled lOP was defined as lOP of 21 mmHg or less at all six diurnal time points. An F-test was used to evaluate differences in standard deviations between groups at each time point.12 The significance level was set at 5% and all tests were a two-way analysis. exfoliation and primary open-angle glaucoma patients for any baseline parameter (p > 0.05). Two patients did not complete the initial phasing protocol due to poor compliance and two others discontinued their participation because of an adverse event while taking apraclonidine.
Results

Patients
Baseline mean intraocular pressure (mmHg :± SD) on timolol maleate 0.5% solution EXG group POAG group 06:00 hours 27.2 :':: 8.2 23.8 :':: 3.3 10:00 hours 27.9 :':: 9.1 23.6 :':: 4.4 14
Intraocular pressure
A difference in baseline lOP values was observed at several time points (at 06:00 and 10:00 hours). Regarding the extent of the decrease in lOP (Table 4) , both the absolute decrease and the percentage reduction were greater in the exfoliation compared with the primary open-angle glaucoma group at most time points (p < 0.05). The exception to this was the early morning (02:00 hours) pressure measurement, when the exfoliation and primary open-angle glaucoma groups had little difference between groups or a reduction from baseline within each group.
Safety
Three of 60 patients (5%) who completed the dosing regimen developed ocular intolerance to apraclonidine over the 2 months of therapy. These patients tolerated the medication sufficiently to complete the diurnal curve successfully. Two additional patients developed ocular intolerance but were dropped from the study prior to their second diurnal curve, providing an overall incidence of 8% (5 of 62 patients).
Regarding ocular and systemic symptoms, 6 patients (10%) reported other side effects potentially related to the use of apraclonidine. Of these, 4 experienced ocular side effects (burning and stinging after administration in 2 patients; pruritus and 'dry eye' sensation in 2 patients) while 2 patients reported related, non-ocular side effects (weakness, dizziness and headache). These side effects did not affect the investigation but resulted in discontinuation of the medication after completion of the diurnal curve.
After completing the study, depending on the outcome of a patient's diurnal curve with apradonidine and timolol and the existence of side effects, the appropriate management steps were taken and all patients were followed routinely to determine the long term stability of the visual field and optic disc.
Discussion
Apradonidine is both an a l -and a2-adrenergic agonist with relative selectivity for a2-receptors. 13 Gharagozloo and associates14 have shown that apradonidine reduces the lOP primarily as an aqueous suppressant.
In patients with primary open-angle glaucoma or ocular hypertension apradonidine has been studied as either monotherapy or adjunctive therapy. As monotherapy, Stewart and associates15 in a multicentre study showed that both 0.25% and 0.5% apradonidine given three times daily have an ocular hypertensive efficacy equal to that of timolol maleate 0.5% at 8 h after administration. However, at the 12 h trough level both concentrations of apradonidine caused approximately a 15% reduction in lOP, which was statistically less than that caused by timolol maleate. These effects were observed for 3 months.15 As adjunctive therapy, in a multicentre study Stewart and associates16 showed that both 0.5% and 1.0% apradonidine given twice a day provided a 14% additional reduction in lOP over timolol maleate alone for up to 3 months.
Apradonidine added to maximally tolerated medical therapy has been evaluated in a multicentre study by In the current study we investigated the effect on the lOP control and safety of adding apradonidine 0.5% monotherapy.ll However, timolol monotherapy did not produce similar lOP levels between groups. Perhaps, however, adjunctive therapy may generally be required to achieve this goal. Whether the pharmacological profile of apraclonidine allows for a greater response in exfoliation glaucoma compared with other glaucoma medicines that might be used adjunctively remains unknown. Safety between groups appeared similar between medicines, with the expected incidence of anterior segment intolerance for 2 months of therapy and the low rate of systemic side effects. 22 In the future it will be important to document whether other medicines commonly used as early adjunctive therapy for glaucoma, such as dorzolomide, brimonidine or latanoprost, could also equalise the lOPs between exfoliation and primary open-angle glaucoma patients when these drugs are added to timolol maleate. Further clinical work is required to determine the optimal treatment regimens and risk factors for progression for patients with exfoliation glaucoma.
This study suggests that apraclonidine, when combined with timolol maleate, is associated with generally similar lOP control in exfoliation glaucoma patients and primary open-angle glaucoma patients.
